Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; and Jason Aboudi Mouabbi, MD; discuss the latest data to inform management of patients with early-stage triple negative breast cancer (TNBC).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate emerging evidence from pivotal trials to determine their impact on evolving treatment paradigms in early-stage and metastatic triple-negative breast cancer (TNBC)
• Incorporate biomarker testing alongside patient-specific factors into personalized treatment plans for patients with TNBC
• Identify key differences in the safety profiles of PARP inhibitors, immunotherapies, and antibody-drug conjugates (ADCs) used for the treatment of TNBC
• Assess unique targets, structures, and mechanisms of novel therapies under investigation for the treatment of TNBC

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals; BioNTech; Daiichi Sankyo, Inc.; and Merck Sharp & Dohme LLC.

Faculty:

Hope S. Rugo, MD, FASCO

Director, Women's Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
San Francisco, CA

Disclosures: Advisor, Consultant, Fee for Service Recipient: BioNTech, Bristol Myers Squibb, Helsinn, Napo; Grant/Research Funding: Institutional research funding to UCSF from Ambryx, AstraZeneca, Daiichi Sankyo, Gilead Sciences, Lilly, Merck & Co., Novartis, Pfizer, F. Hoffman-La Roche/Genentech, Stemline Therapeutics; Institutional research funding to City of Hope from Bicycle Therapeutics, F. Hoffman-La Roche/Genentech, Merck, Stemline Therapeutics

Neil M. Iyengar, MD

Associate Professor, Department of Hematology and Medical Oncology
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Director, Cancer Survivorship Services
Emory University School of Medicine
Atlanta, GA

Disclosures: Consultant/Advisor: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics; Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health; Equity/Ownership: Complement Theory, Bettering Company; Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, National Cancer Institute/NIH; Contracted Research: Novartis, SynDevRx

Heather McArthur, MD, MPH

Professor of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, TX

Disclosures: Consultant: Amgen, Arvinas, AstraZeneca, Bristol Myers Squibb, Calithera, Celgene, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Peregrine, Pfizer, Puma, Seattle Genetics, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, TapImmune; Grant/Research Support: Bristol Myers Squibb, BTG, MedImmune/AstraZeneca, Merck

Jason Aboudi Mouabbi, MD

Assistant Professor, Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Agendia, Aptitude Health, AstraZeneca, BostonGene, Community Health Media, GE HealthCare, PreludeDX, Stemline; Grant/Research Funding: Bristol Myers Squibb, Summit Therapeutics

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including management of metastatic TNBC, go to https://www.gotoper.com/courses/show-me-the-data-redefining-treatment-paradigms-in-triple-negative-breast-cancer-across-the-disease-continuum-h5kn.

Release Date

July 9, 2026

Expiration Date

July 9, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.